1.Studying on CHA tea to serve the community
Journal Reasearch of Vietnam Traditional Medicine and Pharmacy 2003;0(11):14-18
Antihypertensive tea (AHT) was processed from Flos Sophorae, Folium Nelumbii, Radix Achyranthis Bidentatae, Radix Codonopsis Pilosulae, Flos Chrysanthemi, … in the form of filtered bag (3g/bag). Experimental study on subchronic toxicity showed that AHT was non-toxic. Clinical trial carried on 60 patients with hypertension (stages 1 and 2) receiving 9g (3 bags)/day for 30 days revealed that AHT produced good effects: blood tension reduced by 88.3%, clinical symptoms significantly improved, better changes in biochemical and hematological parameters, no side effects
Antihypertensive Agents
;
Antihypertensive Agents
;
Tea
;
Disease
2.Review the block effect on hypertensive attack of sublingual nifedipine (Adalate)
Journal of Practical Medicine 2002;435(11):13-15
Objectives: finding a drug with rapid hypotensive effect, little adverse effects, easy to use for malignant and paroxysmal hypertension, concurrently compare the effects of Adalate in patients who were treated with one or more antihypertensive drugs that their blood pressure were not reduced to the normal level with this in patients who be used only Adalate. Subjects: 50 patients with ages of 18- 80 diagnosed as primary hypertension phase II (10 patients) and phase III (40 patients). Results: 48 patients have a good corresponding with Adalate. Both the diastolic and systolic blood pressures were reduced. The side effects were not common.
Hypertension
;
Antihypertensive Agents
3.Study on anti-hypertensive effects of Bach Hac Acaranthus nasutus Acanthaceae
Pharmaceutical Journal 2002;320(12):11-14
Subjects: liquid extraction (1/1) of acaranthus; frog; dog; rabbit; mice. Method: effects of extraction on blood pressure of dog (effects on adrenaline and nicotine), on isolated heart of frog, on the narcotic effect of hexobarbital in mice. Results: Liquid extraction has synergic effect with hexobarbital, rapid and long hypotension because of adrenaline blocking (a partly block of gland of autonomic nervous system) and vasodilator
Hypertension
;
Antihypertensive Agents
4.Study on antihypertensive action of the receipt: "Hypotensive tisane"
Pharmaceutical Journal 2001;298(2):18-21
Evaluation on the hypotensive action and preliminary finding about active mechanism of "hypotensive tisane" in experimental animals. The trial performed on the dogs shown that "hypotensive tisane" were used at dose of 4g/kg have rapid, long effect and decrease heartbeat. In addition, it had effects on strong vasodilatation, and on the process of lymphocyte form change, and antibacterial effect with some bacteria and fungus
Hypertension
;
Antihypertensive Agents
5.Effect of Qi-training on mitral valve flow in patient with stage I and II of primary hypertension (mild and moderate hypertension)
Journal of Practical Medicine 2002;435(11):56-58
Subjects: The patients who were 16 years of old or more and diagnosed with mild (stage I) and moderate (stage II) hypertension. Method: Open, compared and controlled study. The study group involved 40 patients who performed qi-exercises for 45 minutes per day on 30 days. Control group included 33 patients used fludex. It was found that qi-exercises, but not fludex, had increased the duration of wave-E. There was significant increase of total diastolic duration in study group, but not in control group. Qi-exercises did not change significantly the peak of atrial systole-induced left ventricular filling flow velocity, but fludex provided significant decrease. Left ventricular dystolic function of subjects in study groups did not change, comparing with baseline.
Hypertension
;
Antihypertensive Agents
6.Study on the sadative effect of "antihypertensive tea"
Pharmaceutical Journal 1999;282(10):20-21
A study on the effects of "antihypertensive tea" in the experimental mice has shown that the anti hypertensive tea reduced the natural activities of mice but had no hypnotic effect. The tea had synergic effect when combining with hexobarbital in lasting the sleep duration. The tea at dose of 0.05 - 0.2 ml/10g of body weight of mice (higher 5-20 times of clinical dose) had sedative effect.
Antihypertensive Agents
;
Tea
7.Study on the antihypertensive problem in ischemic stroke patients with hypertension at the ICU-provincial general hospital of Quang Tri
Journal of Practical Medicine 2005;517(8):12-15
We studied 47 ischemic stroke patients with hypertension at the ICU-Quang tri general hospital in the year 2004. These patients were divided into 2 groups: group A consisting of 23 patients whose blood pressure was lowered considerably within 6 early hours and 24 early hours after admission; while the blood pressure of 24 patients of group B was lowered step by step, in a ladder fashion according to the recommendation of WHO. Objective: Clinical comparison (improvement of coma and movement, evidence of cerebral edema) between the 2 groups within 72 hours after hospitalization. Study design: prospective, clinical comparison between 2 disease groups. Results:-Upon admission, the difference of mean Glasgow scores of group A(8.71.1) and group B (8.31.9) is not of statistical significance (p>0.05). At the 24th hour, the mean Glasgow scores of group A and B are 7.5 2.4 and 9.52.6, respectively. By 48 hours, these scores of group A and B are 7.82.4 and 10.62.7, respectively. The mean Glasgow scores of group A and B at the 72nd hour are 7.51.5 and 11.32.5, respectively. It is demonstrated that the mean Glasgow scores at hours 24, 48 and 72 of group B are statistic significant higher than these scores of group A (p<0.01). The clinical improvement of motor paralysis and cerebral edema within 24, 48 and 72 hours after hospital admission is better in group B than in group A, with statistic significance (p<0.01).
Stroke
;
Hypertension
;
Antihypertensive Agents
8.Review of 1,160 patients with hypertension in Viet Tiep hospital in Hai Phong during 1998
Journal of Vietnamese Medicine 2001;256(2):24-29
A study aimed to find frequent of hypertension, the risk factors and the efficacy of the anti-hypertensive agents. Subjectives and methods: medical records of inpatients with hypertension in Viet Tiep hospital, Hai Phong city during 1998. The results have shown that the morbidity rate of hypertension: 8.99% (male: 54.14 and female: 45.86), ages of 41-80: 92.8%, under 40: 3.36%. hypertensive classification according to the WHO: phase I: 13.53%, phase II: 46.38%; phase III: 40.09%. The electrocardiogram: sinal rhythm: 95.41%, arrhythmia: 41.1%, patients admitted to hospital in status of very high blood pressure, systolic pressure: 182+/- 31.04 mmHg, diastolic blood pressure: 103.64 +/- 16.36 mmHg. The blood pressure were reduced significantly after 10.4 days of treatment. Single therapy: 40% patients, double therapy (2 drugs): 37.84% triple therapy: 19.31% and quadrle. therapy (4 drug): 2.85%.
Hypertension
;
Antihypertensive Agents
;
Risk Factors
9.Principles in the Treatment of Hypertension in the Elderly and New Classes of Antihypertensive Agents.
Journal of the Korean Geriatrics Society 2000;4(4):231-243
No abstract available.
Aged*
;
Antihypertensive Agents*
;
Humans
;
Hypertension*
10.Blood pressure-lowering efficacy of Spironolactone in patients with Resistant Hypertension: A meta-analysis
Mithi Kalayaan Zamora ; Jeremiah Vallente ; Raymond Oliva
Philippine Journal of Internal Medicine 2018;56(2):89-95
Introduction:
Resistant hypertension (RH) is defined as a blood pressure (BP) reading that remains above goal despite concurrent use of three optimally dosed antihypertensives of different classes, including a diuretic. Spironolactone, a mineralocorticoid receptor antagonist, has shown significant benefit in reduction of BP in recent trials and is used empirically as an add-on therapy for RH. The researchers’ objective is to evaluate the BP-lowering efficacy of spironolactone in patients with resistant hypertension.
Methods:
A meta-analysis was performed on randomized controlled trials (RCTs) comparing office or home BP reduction using spironolactone with placebo or an alternative drug regimen on top of standard-triple drug therapy among patients with RH. The study was conducted in reference to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).
Results:
Five RCTs were included comprising a total of 662 patients. Three of these studies were found to have low risk of bias while two had unclear risk of bias. Compared to placebo, the addition of spironolactone significantly decreased office systolic BP (weighted mean difference [WMD]= -16.33, 95% confidence interval [CI]=-24.68 to -7.97, P=0.0001) and office diastolic BP (WMD=-6.12, 95% CI= -9.35 to -2.89, P=0.0002). Compared to an alternative drug regimen, additional spironolactone resulted in a significantly greater reduction in office systolic BP (WMD=-4.58mmHg, 95% CI=-7.19, -1.97, P= 0.0006) and home systolic BP (WMD= -4.33, 95% CI= 5.55, -3.12, P< 0.00001); while the addition of spironolactone had no significant difference compared to an alternative drug regimen in reducing office diastolic BP (WMD=-3.35, 95% CI=-12.08 to +5.38, P=0.45) and home diastolic BP (WMD= 0.00, 95 % CI=-0.73 to 0.73, P=1.0).
Conclusion
Spironolactone, when added to triple-drug anti-hypertensive therapy, showed significant reduction of systolic office and home BP. It should be considered as the add-on medication of choice for BP reduction in patients with RH.
Antihypertensive Agents
;
Spironolactone
;
Blood Pressure